CEBPA Mutation

CI-VAR-00002639Explore in graph →CIViC 29

Curated evidence

Evidence by cancer (12 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–12 of 12 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia7
CEBPA Mutation	(prognostic)	Prognostic	B	Supports Better Outcome	3	accepted	EID166 In a group of young (<60 years old) acute myeloid leukemia (exclude acute promyelocytic leukemia) and high-risk MDS patients, those with CEBPA mutations (35/423) showed marginally improved overall sur… (full text at CIViC) PMID 19965647 · Burnett et al., 2010 · Open in CIViC	civic
CEBPA Mutation	(prognostic)	Prognostic	B	Supports Better Outcome	4	accepted	EID167 In young patients (age 16-60) with previously untreated, cytogenetically normal acute myeloid leukemia, CEBPA mutation was significantly associated with complete remission in multivariate analysis (od… (full text at CIViC) PMID 18450602 · Schlenk et al., 2008 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Acute Myeloid Leukemia with CEBPA Mutation5
CEBPA Mutation	(diagnostic)	Diagnostic	B	Supports Positive	3	accepted	EID12172 In this 2021 study, the authors investigated the role of CEBPA mutations in the diagnosis and prognosis of pediatric and young adult acute myeloid leukemia (AML) in 2958 patients enrolled in Children… (full text at CIViC) PMID 33951732 · Tarlock et al., 2021 · Open in CIViC	civic
CEBPA Mutation	(diagnostic)	Diagnostic	B	Supports Positive	4	accepted	EID12173 In this 2022 study, the authors highlighted the diagnostic significance of different types of CEBPA mutations in 4,708 adult AML patients, recruited into the Study Alliance Leukemia trials and spannin… (full text at CIViC) PMID 34320176 · Taube et al., 2022 · Open in CIViC	civic
CEBPA Mutation	(diagnostic)	Diagnostic	B	Supports Positive	4	accepted	EID12174 In this 2022 study, the authors investigated the diagnostic significance of CEBPA mutations in AML, focusing on data from a large cohort of 1,028 patients aged 70 years or younger from the Japanese Mu… (full text at CIViC) PMID 34448807 · Wakita et al., 2022 · Open in CIViC	civic
CEBPA Mutation	(prognostic)	Prognostic	B	Supports Better Outcome	4	accepted	EID12231 In this 2021 study, the authors examined the prognostic implications of CEBPA mutations in pediatric and young adult acute myeloid leukemia (AML) by analyzing 2958 patients enrolled in Children’s Onco… (full text at CIViC) PMID 33951732 · Tarlock et al., 2021 · Open in CIViC	civic
CEBPA Mutation	(diagnostic)	Diagnostic	D	Supports Positive	3	accepted	EID12200 In this 2019 study, the authors investigated the diagnostic significance of CEBPA mutations in AML by analyzing how the order of these mutations influences disease development in a mouse model that re… (full text at CIViC) PMID 31784538 · Braun et al., 2019 · Open in CIViC	civic